COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature

Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshanqeeti, Shatha, Bhargava, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308388/
https://www.ncbi.nlm.nih.gov/pubmed/35898366
http://dx.doi.org/10.7759/cureus.26239
Descripción
Sumario:Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.

Ejemplares similares